NCT00207792

Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Centre National de Greffe de Moelle Osseuse · Other Government
• Sex: All
• Age: 16 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear. The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor \[G-CSF\] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.

Conditions

• Graft vs Host Disease

Interventions

Type	Name	Description
DRUG	filgrastim

Timeline

• Start date: 2005-07-01
• First posted: 2005-09-21
• Last updated: 2007-11-06

Locations

1 site across 1 country: Tunisia